Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults

Nutrition and Diabetes

Volumn 4, Issue 10, 2014, Pages

  Hanamatsu, H ^a   Ohnishi, S ^a,b   Sakai, S ^a   Yuyama, K ^a   Mitsutake, S ^a,c   Takeda, H ^a   Hashino, S ^a   Igarashi, Y ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CERAMIDE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SPHINGOMYELIN;

ADULT; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DYSLIPIDEMIA; FAT MASS; FEMALE; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; LIVER FUNCTION; MALE; MOLECULE; NONALCOHOLIC FATTY LIVER; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

EID: 84927749424     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.38     Document Type: Article

References (34)

1. Lee JM. Why young adults hold the key to assessing the obesity epidemic in children. Arch Pediatr Adolesc Med 2008; 162: 682-687.
2. Das UN. Obesity: genes, brain, gut, and environment. Nutrition 2010; 26: 459-473.
3. Yuyama K, Mitsutake S, Igarashi Y. Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer's disease. Biochim Biophys Acta 2014; 1841: 793-798.
4. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci 2012; 1271: 37-43.
5. Merrill AH. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 2002; 277: 25843-25846.
6. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139-150.
7. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E et al. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 2006; 1758: 1864-1884.
8. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 2010; 31: 398-408.
9. Ussher JR, Koves TR, Cadete VJ, Zhang L, Jaswal JS, Swyrd SJ et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010; 59: 2453-2464.
10. Kurek K, Piotrowska DM, Wiesioek-Kurek P, Lukaszuk B, Chabowski A, Górski J et al. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int 2014; 34: 1074-1083.
11. Mitsutake S, Zama K, Yokota H, Yoshida T, Tanaka M, Mitsui M et al. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes. J Biol Chem 2011; 286: 28544-28555.
12. Mitsutake S, Date T, Yokota H, Sugiura M, Kohama T, Igarashi Y. Ceramide kinase deficiency improves diet-induced obesity and insulin resistance. FEBS Lett 2012; 586: 1300-1305.
13. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20: 2614-2618.
14. Schlitt A, Blankenberg S, Yan D, von Gizycki H, Buerke M, Werdan K et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) 2006; 3: 5.
15. Ichi I, Nakahara K, Miyashita Y, Hidaka A, Kutsukake S, Inoue K et al. Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids 2006; 41: 859-863.
16. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009; 58: 337-343.
17. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 1983; 139: 43-50.
18. Lorenzo AD, Andreoli A. Segmental bioelectrical impedance analysis. Curr Opin Clin Nutr Metab Care 2003; 6: 551-555.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001; 34: 583-588.
21. Merrill AH, Sullards MC, Allegood JC, Kelly S, Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005; 36: 207-224.
22. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-Alcoholic fatty liver disease and non-Alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
23. Onat A, Can G, Kaya H, Hergenç G. "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol 2010; 4: 89-98.
24. Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gadban MM, Rembiesa B et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res 2010; 51: 3074-3087.
25. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
26. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-Alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 1996; 271: 13018-13022.
27. Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014; 20: 575-584.
28. Brozinick JT, Hawkins E, Hoang Bui H, Kuo MS, Tan B, Kievit P et al. Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet. Int J Obes (Lond) 2013; 37: 1064-1070.
29. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
30. Li Y, Dong J, Ding T, Kuo MS, Cao G, Jiang XC et al. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-Activated receptor gamma2 suppression. Arterioscler Thromb Vasc Biol 2013; 33: 1513-1520.
31. Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 2012; 23: 365-371.
32. Chen X, Sun A, Zou Y, Ge J, Lazar JM, Jiang XC. Impact of sphingomyelin levels on coronary heart disease and left ventricular systolic function in humans. Nutr Metab (Lond) 2011; 8: 25.
33. Ohkawa R, Kishimoto T, Kurano M, Dohi T, Miyauchi K, Daida H et al. Development of an enzymatic assay for sphingomyelin with rapid and automatable performances: analysis in healthy subjects and coronary heart disease patients. Clin Biochem 2012; 45: 1463-1470.
34. Onat A, Altu Cakmak H, Can G, Yüksel M, Körolu B, Yüksel H. Serum total and high-density lipoprotein phospholipids: Independent predictive value for cardiometabolic risk. Clin Nutr 2014; 33: 815-822.